These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3819527)

  • 1. Intra-adipose administration of monoacetyldapsone to healthy volunteers.
    Pieters FA; Zuidema J
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):510-6. PubMed ID: 3819527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained release properties of an intra-adiposely administered dapsone depot injection.
    Pieters FA; Zuidema J; Merkus FW
    Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):383-8. PubMed ID: 3746042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone.
    Pieters FA; Woonink F; Zuidema J
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):10-20. PubMed ID: 3373080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular injection of dapsone in therapy for leprosy: a new approach.
    Modderman ES; Huikeshoven H; Zuidema J; Leiker DL; Merkus FW
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):51-6. PubMed ID: 7061179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in the absorption of dapsone after intramuscular injection.
    Modderman ES; Merkus FW; Zuidema J; Hilbers HW; Warndorff T
    Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):359-65. PubMed ID: 6685698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
    Koda RT; Dubé MP; Li WY; Chatterjee DJ; Stansell JD; Sattler FR
    J Clin Pharmacol; 1999 Mar; 39(3):268-74. PubMed ID: 10073326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The occurrence of dapsone residues following a one-time oral, intramuscular and intramammary application in healthy dairy cows].
    van Gend HW; Brinkman MB; Mol H; Kommerij R; van der Kreek FW
    Tijdschr Diergeneeskd; 1986 Oct; 111(19):911-20. PubMed ID: 3764871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.
    Lammintausta K; Kangas L; Lammintausta R
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):159-63. PubMed ID: 447435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography.
    Lee HS; Ti TY; Lee PS; Yap CL
    Ther Drug Monit; 1985; 7(4):415-20. PubMed ID: 3909534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of dapsone as a marker of acetylator phenotypes.
    Wiggan EB; Dennis S; Reele SB; Luke DR
    Int J Clin Pharmacol Ther Toxicol; 1991 Jul; 29(7):262-8. PubMed ID: 1889912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.
    Garg SK; Kumar B; Bakaya V; Lal R; Shukla VK; Kaur S
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):552-4. PubMed ID: 3243659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
    Guo R; Thormann W; Lauterberg B
    Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
    May DG; Porter JA; Uetrecht JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1990 Dec; 48(6):619-27. PubMed ID: 2249373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of age, sex and body weight on the dapsone acetylation phenotype.
    Philip PA; Gayed SL; Rogers HJ; Crome P
    Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.